Business Description
![Regeneron Pharmaceuticals Inc Regeneron Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C000008R4.png?14)
Regeneron Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75886F1075
Share Class Description:
REGN: Ordinary SharesCompare
Compare
Traded in other countries / regions
REGN.USA0R2M.UKREGN34.BrazilREGN.MexicoRGO.GermanyREGN.Austria1REGN.Italy IPO Date
1991-04-02Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.89 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.59 | |||||
Interest Coverage | 56.1 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 11.82 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16 | |||||
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | 7.9 | |||||
3-Year FCF Growth Rate | 22.8 | |||||
3-Year Book Growth Rate | 32.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 9.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.95 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 90.99 | |||||
9-Day RSI | 82.8 | |||||
14-Day RSI | 76.33 | |||||
6-1 Month Momentum % | 14.33 | |||||
12-1 Month Momentum % | 25.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.27 | |||||
Quick Ratio | 4.51 | |||||
Cash Ratio | 2.94 | |||||
Days Inventory | 520.98 | |||||
Days Sales Outstanding | 148.86 | |||||
Days Payable | 120.63 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | 1.54 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.32 | |||||
Operating Margin % | 30.45 | |||||
Net Margin % | 29.45 | |||||
FCF Margin % | 30 | |||||
ROE % | 15.38 | |||||
ROA % | 12.03 | |||||
ROIC % | 19.71 | |||||
ROC (Joel Greenblatt) % | 45.67 | |||||
ROCE % | 14.33 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 30.7 | |||||
Forward PE Ratio | 23.76 | |||||
PE Ratio without NRI | 27.04 | |||||
Shiller PE Ratio | 36.54 | |||||
Price-to-Owner-Earnings | 41.57 | |||||
PEG Ratio | 1.53 | |||||
PS Ratio | 9.03 | |||||
PB Ratio | 4.24 | |||||
Price-to-Tangible-Book | 4.42 | |||||
Price-to-Free-Cash-Flow | 30.15 | |||||
Price-to-Operating-Cash-Flow | 25 | |||||
EV-to-EBIT | 26.1 | |||||
EV-to-Forward-EBIT | 20.84 | |||||
EV-to-EBITDA | 23.6 | |||||
EV-to-Forward-EBITDA | 19.63 | |||||
EV-to-Revenue | 8.2 | |||||
EV-to-Forward-Revenue | 7.77 | |||||
EV-to-FCF | 27.32 | |||||
Price-to-Projected-FCF | 1.69 | |||||
Price-to-DCF (Earnings Based) | 0.87 | |||||
Price-to-DCF (FCF Based) | 0.97 | |||||
Price-to-Median-PS-Value | 1.15 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.43 | |||||
Price-to-Graham-Number | 2.3 | |||||
Price-to-Net-Current-Asset-Value | 9.96 | |||||
Price-to-Net-Cash | 36.45 | |||||
Earnings Yield (Greenblatt) % | 3.83 | |||||
FCF Yield % | 3.43 | |||||
Forward Rate of Return (Yacktman) % | 21.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:REGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regeneron Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 13,100.1 | ||
EPS (TTM) ($) | 33.85 | ||
Beta | 0.48 | ||
Volatility % | 20.52 | ||
14-Day RSI | 76.33 | ||
14-Day ATR ($) | 17.527359 | ||
20-Day SMA ($) | 997.942 | ||
12-1 Month Momentum % | 25.44 | ||
52-Week Range ($) | 684.805 - 1052.34 | ||
Shares Outstanding (Mil) | 110.19 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Regeneron Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Regeneron Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Regeneron Pharmaceuticals Inc Frequently Asked Questions
What is Regeneron Pharmaceuticals Inc(REGN)'s stock price today?
The current price of REGN is $1039.11. The 52 week high of REGN is $1052.34 and 52 week low is $684.81.
When is next earnings date of Regeneron Pharmaceuticals Inc(REGN)?
The next earnings date of Regeneron Pharmaceuticals Inc(REGN) is 2024-08-02 Est..
Does Regeneron Pharmaceuticals Inc(REGN) pay dividends? If so, how much?
Regeneron Pharmaceuticals Inc(REGN) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |